On March 28, 2024, the Qingdao High-End Intelligent Manufacturing Industrial Base for Life and Health Technology was officially launched, with a signing ceremony for the first batch of resident companies held in Qingdao's Shibei District. The event featured speeches from Jiang Baoguo, Academician of the Chinese Academy of Engineering and Director of the National Trauma Medical Center, and Geng Tao, Member of the Standing Committee of the Qingdao Municipal Party Committee and Vice Mayor. The event was attended by Bo Tao, Vice Chairman of the Qingdao CPPCC and Director of the Qingdao Municipal Health Commission, along with other key officials from relevant city and district departments, and Fu Gang, Chairman of Baheal Pharma Group. At the ceremony, four innovative companies incubated by Baheal Pharma Group signed agreements to become the first residents of the base. Additionally, the Qingdao Huizhu Baheal Medical and Health Industrial Investment Fund was officially signed.

Currently, the country is vigorously encouraging technological innovation to accelerate the formation of new productive forces. Technological innovation can give rise to new industries, models, and drivers, and is a core element in developing new productive forces. In 2023, Shibei District released the "Three-Year Action Plan for the Development of the Life and Health Industry in Shibei District," proposing to build Qingdao's "Health Valley" with Baheal Pharma Group as the leader, introducing high-precision health industry resources. As an important component of this action plan, the High-End Intelligent Manufacturing Industrial Base for Life and Health Technology aims to become an industrial cluster integrating medical services, medical research and development, headquarters offices, and technological innovation incubation. Once operational, the project will significantly enhance the aggregation capacity and scientific innovation level of the medical device industry in Shibei and across Qingdao, becoming a model for the development of Qingdao's medical device industry.

The first phase of the Intelligent Manufacturing Industrial Base will initially host four innovative medical device companies incubated by Baheal Pharma Group: Huake Pioneer, Baheal  InnoVision, BainenKangjian, and Wehealth.

According to reports, Huake Pioneer will produce X-band medical linear accelerators that breakthrough "neck-choking" technologies within the park. Baheal InnoVision will focus on producing high-sensitivity SPECT/CT for nuclear medicine. BainenKangjian will specialize in the research, development, and production of high-definition medical hard mirrors, providing comprehensive solutions for clinical diagnosis and minimally invasive surgical treatment. Wehealth will engage in the development of intelligent cardiovascular-related hardware and software, and will manufacture portable home ECG devices capable of monitoring myocardial ischemia within the park.

At the ceremony, the "Qingdao Huizhu Baheal Medical and Health Industrial Investment Fund" was also officially signed. The fund has a fundraising target of 1 billion RMB. Managed by Baheal Zhongxin Fund, the fund will select and invest in truly innovative projects with clinical application value, leveraging Baheal Pharma Group's extensive industrial resources to promote the commercialization and clinical application of scientific research results.

"The proposal of new productive forces has set higher requirements for the development of the medical and health industry. In the pharmaceutical and health field, only by reshaping the value chain through technological innovation can we promote and achieve high-quality industrial development," said Fu Gang, Chairman of Baheal Pharma Group. As a health industry group driven by technological innovation, Baheal will utilize its resource advantages and incubation capabilities to continuously promote the aggregation of high-quality medical and health resources and high-end talents. This effort will drive the domestic substitution of "neck-choking" technologies in high-end medical devices and the development of innovative drugs, contributing to the innovative development of China's health industry.

In recent years, Baheal Pharma Group, as an "industrial investor," has focused on three major value tracks: innovative drugs, high-end medical devices, and basic research platforms. Partnering with national-level research institutes, Baheal has been investing in and incubating original Chinese pharmaceutical and health products with independent intellectual property rights, optimizing medical scenarios through technological innovation. Currently, Baheal has established an industrial base layout with "three locations and three centers" in Qingdao, Beijing, and Langfang. The resources of these three locations are complementary, actively building a bridge for the transformation of scientific research results into real productivity. Significant progress has already been made in areas such as fully magnetic levitation artificial hearts, innovative nuclear medicine drugs, SPECT/CT, electromagnetic navigation puncture guidance devices, and innovative anti-tumor and bone regeneration drugs.

In the future, Baheal will fully leverage its resource advantages and collaborative capabilities to continuously promote the aggregation of high-quality medical and health resources, accelerate the transformation of high-quality medical achievements, and contribute to the innovative development of the industry.